TARBP2: A Promising Drug Target and Biomarker for Cancer Treatment

Target Name: TARBP2

NCBI ID: G6895

TARBP2

TARBP2: A Promising Drug Target and Biomarker for Cancer Treatment

Abstract:

TARBP2 (TARBP2, RISC loading complex RNA binding subunit), a gene encoding a protein that belongs to the TAR family, has been identified as a promising drug target and biomarker for cancer treatment. The TARBP2 gene has been shown to play a crucial role in the regulation of RNA homeostasis, which is a critical process that ensures the correct translation of genetic information into protein. Imbalances in RNA homeostasis have been implicated in the development and progression of numerous diseases, including cancer. Therefore, targeting TARBP2 has the potential to offer new therapeutic approaches for cancer treatment.

Introduction:

The regulation of RNA homeostasis is a critical process that ensures the correct translation of genetic information into proteins. RNA homeostasis is regulated by a complex interplay of factors, including RNA binding proteins (RBP), transfer RNA (tRNA), and small RNA regulatory proteins (siRNA), among others. One of the key components of this complex regulatory system is TARBP2, a protein that belongs to the TAR family.

TARBP2 function:

TARBP2 is a 22-kDa protein that is expressed in various cell types, including neurons, breast cells, and cancer cells. TARBP2 functions as an RNA binding protein, specifically, it can bind to specific RNA molecules with high affinity. TARBP2 has been shown to play a critical role in regulating the expression of target genes, including cancer genes.

TARBP2 has been shown to promote the loading of small RNA molecules, such as siRNA and microRNA (miRNA), into the endoplasmic reticulum (ER), which is a protein that retrieves and transports proteins from the cytoplasm to the ER. The ER is a site of translation of pre-mRNA, which is converted into protein by the ribosome. Therefore, TARBP2 promotes the translation of miRNA and siRNA into the ER, where they can be processed and degraded.

In addition to promoting miRNA and siRNA loading, TARBP2 has also been shown to regulate the stability of pre-mRNA in the ER. Pre-mRNA stability is critical for efficient translation into protein, and TARBP2 has been shown to promote the stability of pre-mRNA. mRNA in the ER by preventing its degradation and interaction with foreign proteins.

TARBP2 as a drug target:

TARBP2 has been identified as a promising drug target for cancer treatment due to its involvement in the regulation of RNA homeostasis. Imbalances in RNA homeostasis have been implicated in the development and progression of numerous diseases, including cancer. Therefore, targeting TARBP2 has the potential to offer new therapeutic approaches for cancer treatment.

Targeting TARBP2 can be achieved through several different mechanisms, including small molecule inhibitors, RNA interference, and CRISPR/Cas9 genome editing. Small molecule inhibitors can be used to reduce TARBP2 function by inhibiting its binding to RNA molecules. RNA interference can be used to knockdown TARBP2 expression in cancer cells. CRISPR/Cas9 genome editing can be used to introduce genetic mutations in TARBP2 to alter its function.

TARBP2 as a biomarker:

TARBP2 has also been identified as a potential biomarker for cancer diagnosis and treatment. The expression of TARBP2 has been shown to be elevated in various types of cancer, including breast cancer and lung cancer. Therefore, TARBP2 can be used as a biomarker for cancer diagnosis and treatment.

Conclusion:

TARBP2 is a protein that plays a crucial role in regulating RNA homeostasis and has been shown to promote the loading of small RNA molecules into the endoplasmic reticulum. TARBP2 has the potential to be a drug target for cancer treatment due to its involvement in the regulation of RNA homeostasis. Further research is needed to

Protein Name: TARBP2 Subunit Of RISC Loading Complex

Functions: Required for formation of the RNA induced silencing complex (RISC). Component of the RISC loading complex (RLC), also known as the micro-RNA (miRNA) loading complex (miRLC), which is composed of DICER1, AGO2 and TARBP2. Within the RLC/miRLC, DICER1 and TARBP2 are required to process precursor miRNAs (pre-miRNAs) to mature miRNAs and then load them onto AGO2. AGO2 bound to the mature miRNA constitutes the minimal RISC and may subsequently dissociate from DICER1 and TARBP2. May also play a role in the production of short interfering RNAs (siRNAs) from double-stranded RNA (dsRNA) by DICER1

The "TARBP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TARBP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets